Feedback / Questions
XB002 - Exelixis
XL102 - Exelixis
XB628 - Exelixis
XB014 - Exelixis, Invenra
XB010 - Exelixis
ADU-1805 - Exelixis, Sairopa
alphalex-exatecan (CBX-12) - Cybrexa Therap, Exelixis
https://www.businesswire.com/news/home/20230207005453/en/Exelixis-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update
Feb 7, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next